Xiang Li-Li, Qiu Guo-Qiang, Xie Xiao-Bao, Cen Jian-Nong, Hu Shao-Yan, Gu Wei-Ying
Department of Hematology, The Central Hospital of Xuzhou, Xuzhou 221009, Jiangsu Province, China.
Laboratory of Hematology, Third Hospital Affiliated to Suzhou University, The First People's Hospital of Changzhou, Changzhou 213003, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Feb;25(1):61-65. doi: 10.7534/j.issn.1009-2137.2017.01.010.
To investigate the percentage of blasts with the CD34/CD38/CD123 phenotype in de novo acute myeloid leukemia (AML) patients and analyse its correlation with prognosis.
The percentage of CD34/CD38/CD123 cells in the blast population of 148 newly diagnosed patients with AML was determined by using flow cytometry and its correlation with complete response, disease-free survival and overall survival were evaluated.
The median percentage of CD34/CD38/CD123 cells in newly diagnosed patients was 2.8% (ranged from 0.01 to 67%). The high expression of CD34/CD38/CD123 in AML patients positively correlated with the NPM1 wild-type (χ=5.194,P<0.05), but did not relate with the positive FLT3-ITD mutations (χ=0.418,P>0.05). Further multivariable analysis showed that the higher expression of the CD34/CD38/CD123 was associated with lower complete remission (P<0.05), worse disease-free survival(P<0.01) and shorter overall survival(P<0.01) in AML patients.
The percentage of CD34/CD38/CD123 cells at diagnosis significantly correlates with the response to treatment and survival. This prognostic marker may be used to rapidly identify the risk of treatment failure in clinical practice.
研究初诊急性髓系白血病（AML）患者中具有CD34/CD38/CD123表型的原始细胞百分比，并分析其与预后的相关性。
采用流式细胞术测定148例新诊断AML患者原始细胞群中CD34/CD38/CD123细胞的百分比，并评估其与完全缓解、无病生存期和总生存期的相关性。
新诊断患者中CD34/CD38/CD123细胞的中位百分比为2.8%（范围为0.01%至67%）。AML患者中CD34/CD38/CD123的高表达与NPM1野生型呈正相关（χ=5.194，P<0.05），但与FLT3-ITD阳性突变无关（χ=0.418，P>0.05）。进一步多变量分析显示，CD34/CD38/CD123表达较高与AML患者较低的完全缓解率（P<0.05）、较差的无病生存期（P<0.01）和较短的总生存期（P<0.01）相关。
诊断时CD34/CD38/CD123细胞的百分比与治疗反应和生存期显著相关。这一预后标志物可用于临床实践中快速识别治疗失败风险。
